ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 198503" data-attributes="member: 13851"><div style="text-align: justify; max-width: %s">[URL unfurl="true"]https://www.globenewswire.com/news-release/2021/03/30/2201451/0/en/Acerus-Announces-Expansion-of-NATESTO-Distribution-Worldwide.html[/URL]</div> </p><div style="text-align: justify; max-width: %s"><strong>Acerus Announces Expansion of NATESTO® Distribution Worldwide</strong></div> </p><div style="text-align: justify; max-width: %s"><strong>Maylen Farma to Market Treatment in 20 Countries across Europe, Central Asia, and the Middle East</strong></div> </p><div style="text-align: justify; max-width: %s"><em>TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- <strong>Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement granting Maylen Farma (“Maylen”) the exclusive rights to market NATESTO® in 20 countries across Europe, Central Asia, and the Middle East. </strong>Maylen is a privately-owned pharmaceutical company based in Lugano, Switzerland that specializes in bringing innovative pharmaceutical products and healthcare services to patients in emerging markets.<strong> Nations covered by the agreement with Acerus include Belarus, Georgia, and Ukraine; Azerbaijan, Uzbekistan, Tajikistan, Kazakhstan, and Kyrgyzstan; Albania, Kosovo, North Macedonia, Serbia, and Bosnia and Herzegovina; the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Jordan, and Lebanon.</strong></em></div> </p><div style="text-align: justify; max-width: %s"><em>“We are delighted to be partnering with Maylen in the commercialization of NATESTO® across these 20 rapidly expanding markets,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “Maylen’s extensive reach and expertise will provide – assuming regulatory approval across all covered countries – access to a combined population of approximately 220 million. </em><strong><em><u>Based on current development plans, Maylen is confident in its ability to gain the requisite approvals and begin selling NATESTO® in up to five countries by the end of 2021, with potentially seven additional nations in 2022. We are excited by the opportunity this will provide to bolster our top-line growth trajectory</u>.”</em></strong></div></blockquote><p></p>
[QUOTE="madman, post: 198503, member: 13851"] [JUSTIFY='%s'][URL unfurl="true"]https://www.globenewswire.com/news-release/2021/03/30/2201451/0/en/Acerus-Announces-Expansion-of-NATESTO-Distribution-Worldwide.html[/URL][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][B]Acerus Announces Expansion of NATESTO® Distribution Worldwide[/B][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][B]Maylen Farma to Market Treatment in 20 Countries across Europe, Central Asia, and the Middle East[/B][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][I]TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- [B]Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement granting Maylen Farma (“Maylen”) the exclusive rights to market NATESTO® in 20 countries across Europe, Central Asia, and the Middle East. [/B]Maylen is a privately-owned pharmaceutical company based in Lugano, Switzerland that specializes in bringing innovative pharmaceutical products and healthcare services to patients in emerging markets.[B] Nations covered by the agreement with Acerus include Belarus, Georgia, and Ukraine; Azerbaijan, Uzbekistan, Tajikistan, Kazakhstan, and Kyrgyzstan; Albania, Kosovo, North Macedonia, Serbia, and Bosnia and Herzegovina; the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Jordan, and Lebanon.[/B][/I][/JUSTIFY] [JUSTIFY='%s'][I][/I][/JUSTIFY] [JUSTIFY='%s'][I]“We are delighted to be partnering with Maylen in the commercialization of NATESTO® across these 20 rapidly expanding markets,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “Maylen’s extensive reach and expertise will provide – assuming regulatory approval across all covered countries – access to a combined population of approximately 220 million. [/I][B][I][U]Based on current development plans, Maylen is confident in its ability to gain the requisite approvals and begin selling NATESTO® in up to five countries by the end of 2021, with potentially seven additional nations in 2022. We are excited by the opportunity this will provide to bolster our top-line growth trajectory[/U].”[/I][/B][/JUSTIFY] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top